









市场行情
/
股票
/
nasdaq-abus
/

Arbutus Biopharma Corp

ABUS

3.350USD

+0.080+2.44%

交易中（美东）报价延迟15分钟

641.41M总市值

亏损市盈率 TTM



Arbutus Biopharma Corp

3.350

+0.080+2.44%

概览公司财务

Arbutus Biopharma Corporation 是一家临床阶段的生物制药公司。该公司正在利用其病毒学专业知识来识别和开发具有不同作用机制的新型疗法，这些疗法可以结合起来为慢性乙型肝炎病毒 (cHBV) 感染患者提供功能性治愈。其 HBV 产品线包括 Imdusiran 和 AB-101。Imdusiran 是其专有的共轭 GalNAc 皮下递送 RNAi 治疗产品候选物。AB-101 是一种口服 PD-L1 抑制剂，有可能通过抑制 PD-L1 重新唤醒患者的 HBV 特异性免疫反应。其产品线包括两种针对 HBV 病毒生命周期各个步骤的候选产品，由各种程序组成：RNAi 治疗（imdusiran，AB-729）和口服 PD-L1 抑制剂（AB-101）。RNAi 疗法利用细胞内的天然途径通过消除基因编码的致病蛋白质来沉默基因。

公司简介

公司代码ABUS

公司名称Arbutus Biopharma Corp

上市日期Nov 13, 2010

CEOMs. Lindsay Androski, J.D.

员工数量44

证券类型Ordinary Share

年结日Nov 13

公司地址701 Veterans Circle

城市WARMINSTER

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编18974

电话16044193200

网址https://www.arbutusbio.com/

公司代码ABUS

上市日期Nov 13, 2010

CEOMs. Lindsay Androski, J.D.

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Joseph Bishop

Independent Director

Mr. Matthew Gline

Independent Director

Mr. Anuj Hasija

Independent Director

Mr. Robert Alan Beardsley

Independent Director

Ms. Lindsay Androski, J.D.

Chairman of the Board, President, Chief Executive Officer

Mr. Tuan Nguyen

Chief Financial Officer

名称

名称/职务

职务

持股

持股变动

Mr. Joseph Bishop

Independent Director

Mr. Matthew Gline

Independent Director

Mr. Anuj Hasija

Independent Director

Mr. Robert Alan Beardsley

Independent Director

Ms. Lindsay Androski, J.D.

Chairman of the Board, President, Chief Executive Officer

Mr. Tuan Nguyen

Chief Financial Officer

收入明细

暂无数据

暂无数据

业务

地区

暂无数据

股东统计

更新时间: 5月17日周六

持股股东

股东类型

持股股东

占比

Roivant Sciences Ltd.

20.28%

Morgan Stanley Investment Management Inc. (US)

11.85%

Whitefort Capital Management, LP

6.95%

BlackRock Institutional Trust Company, N.A.

5.96%

Two Seas Capital LP

4.94%

Other

50.02%

持股股东

占比

Roivant Sciences Ltd.

20.28%

Morgan Stanley Investment Management Inc. (US)

11.85%

Whitefort Capital Management, LP

6.95%

BlackRock Institutional Trust Company, N.A.

5.96%

Two Seas Capital LP

4.94%

Other

50.02%

股东类型

持股股东

占比

Hedge Fund

21.71%

Corporation

20.28%

Investment Advisor/Hedge Fund

19.55%

Investment Advisor

15.47%

Research Firm

2.47%

Individual Investor

1.64%

Bank and Trust

0.27%

Pension Fund

0.17%

Venture Capital

0.04%

Other

18.41%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

297

156.32M

81.62%

+5.47M

2025Q1

315

155.95M

81.43%

+5.02M

2024Q4

297

147.19M

78.79%

-1.77M

2024Q3

299

144.28M

77.46%

-1.67M

2024Q2

274

139.38M

74.89%

+5.03M

2024Q1

272

125.84M

69.82%

-6.90M

2023Q4

273

121.03M

71.96%

-8.47M

2023Q3

278

113.50M

68.12%

-7.67M

2023Q2

283

108.80M

65.65%

-8.52M

2023Q1

288

105.13M

63.70%

-2.80M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

Roivant Sciences Ltd.

38.85M

20.28%

Feb 25, 2025

Morgan Stanley Investment Management Inc. (US)

22.70M

11.85%

+1.47M

+6.92%

Mar 31, 2025

Whitefort Capital Management, LP

13.31M

6.95%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

11.41M

5.96%

-258.87K

-2.22%

Mar 31, 2025

Two Seas Capital LP

9.47M

4.94%

+725.00K

+8.29%

Mar 31, 2025

The Vanguard Group, Inc.

8.92M

4.66%

-27.04K

-0.30%

Mar 31, 2025

State Street Global Advisors (US)

4.36M

2.28%

-663.12K

-13.19%

Mar 31, 2025

Geode Capital Management, L.L.C.

3.54M

1.85%

+59.01K

+1.69%

Mar 31, 2025

Woodline Partners LP

2.66M

1.39%

+1.68M

+173.33%

Mar 31, 2025

FourSixThree Capital LP

2.45M

1.28%

+2.45M

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

Virtus LifeSci Biotech Clinical Trials ETF

0.78%

Invesco NASDAQ Future Gen 200 ETF

0.41%

Hypatia Women CEO ETF

0.16%

iShares Micro-Cap ETF

0.11%

iShares MSCI USA Small-Cap Min Vol Factor ETF

0.08%

Invesco Nasdaq Biotechnology ETF

0.07%

ProShares Ultra Nasdaq Biotechnology

0.07%

SPDR S&P Biotech ETF

0.07%

iShares Biotechnology ETF

0.05%

iShares ESG Aware MSCI USA Small-Cap ETF

0.05%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.78%

Invesco NASDAQ Future Gen 200 ETF

占比0.41%

Hypatia Women CEO ETF

占比0.16%

iShares Micro-Cap ETF

占比0.11%

iShares MSCI USA Small-Cap Min Vol Factor ETF

占比0.08%

Invesco Nasdaq Biotechnology ETF

占比0.07%

ProShares Ultra Nasdaq Biotechnology

占比0.07%

SPDR S&P Biotech ETF

占比0.07%

iShares Biotechnology ETF

占比0.05%

iShares ESG Aware MSCI USA Small-Cap ETF

占比0.05%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

KeyAI

